The FAIR Act amends the Federal Food, Drug, and Cosmetic Act to let sponsors request that the FDA grant “reciprocal marketing approval” for drugs and biologics lawfully authorized by specified foreign regulators. It also creates a parallel pathway to allow clinical investigations already authorized by those regulators to proceed in the United States.
Both pathways impose a 30‑day statutory decision clock and carry post‑market and labeling obligations.
This approach targets products for immediately life‑threatening diseases and is intended to shorten U.S. access timelines and attract or retain clinical research. For industry and regulators, the bill replaces duplicated initial review work with a rapid, reliance‑based process — shifting emphasis to post‑market surveillance, interagency judgment about which foreign regulators qualify, and the operational capacity to execute fast reviews and safety monitoring.
At a Glance
What It Does
The bill creates two reciprocal mechanisms: (1) a ‘reciprocal marketing approval’ that deems certain foreign‑authorized drugs equivalent to an FDA approval for marketing in the U.S.; and (2) a reciprocal allowance to conduct clinical trials in the U.S. based on authorization by a trusted foreign regulator. The Secretary must approve or deny requests within 30 days and may require labeling and post‑market studies during that period.
Who It Affects
Sponsors of drugs and biologics for immediately life‑threatening conditions, the FDA (including review and post‑market surveillance units), U.S. clinical trial sites and IRBs, payers facing coverage decisions for rapidly authorized therapies, and the listed foreign regulators (initially EMA, MHRA, Health Canada).
Why It Matters
The bill institutionalizes regulatory reliance: it can materially shorten time to market and expand trial participation in the U.S. but also shifts risk management toward post‑market systems and intergovernmental judgment about which regulators qualify as ‘trusted.’ That rebalances incentives across sponsors, reviewers, and clinical sites.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The FAIR Act adds two discrete reliance pathways to federal law. First, it inserts a new section (524C) into the FD&C Act authorizing the FDA to grant a ‘reciprocal marketing approval’ when a sponsor shows the product is lawfully marketed abroad under an authorization from a trusted international regulatory authority, is not already approved in the U.S., and is intended for an immediately life‑threatening disease.
The Secretary must be satisfied that neither the foreign authorization nor any U.S. approval has been rescinded for safety reasons. The statute requires sponsors to submit the foreign dossier (with English translation as needed) and empowers the FDA to finalize U.S. labeling and any post‑market study requirements during the statutory review window.
Second, the bill creates a reciprocal allowance for clinical investigations by adding section 569B–1 to the FD&C Act. A manufacturer can submit the foreign authorization and supporting documentation to obtain authorization to run the same trial in the U.S. The Secretary treats the submission as equivalent to the information needed under existing investigational new drug provisions and must issue a decision within 30 days.
The bill permits the FDA to request protocol modifications before the 30‑day clock expires but still requires a decision within that timeframe.Across both pathways the Secretary has explicit authority to withdraw or suspend approvals if new clinical or real‑world evidence shows unreasonable risk, or if the originating foreign regulator rescinds its authorization. The law gives the FDA discretion to implement phase‑out plans to protect patients if it withdraws an approval, mandates that reciprocal requests be treated as fee‑paying applications under chapter VII, and requires a comprehensive five‑year report to Congress evaluating safety, access, and program outcomes.
The statutory definition of “trusted international regulatory authority” lists EMA, MHRA, and Health Canada and allows HHS to designate additional authorities.
The Five Things You Need to Know
The Secretary must grant or deny reciprocal marketing approval or clinical‑trial allowance within 30 days of receiving a complete request.
The bill initially identifies three ‘trusted’ regulators — the European Medicines Agency (EMA), the UK’s MHRA, and Health Canada — and allows the HHS Secretary to add others.
Reciprocal pathways are limited to products intended to treat an “immediately life‑threatening” disease per the existing 21 C.F.R. definition.
The Secretary may suspend or withdraw reciprocal approval for new safety signals or if the foreign regulator rescinds authorization, and adverse events within the first 30 days can trigger immediate cessation of marketing.
Requests are treated as applications under chapter VII for fee purposes and must include the foreign regulator’s dossier (with English translations where necessary).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creates the reciprocal marketing‑approval framework
This provision authorizes the FDA to deem a foreign‑authorized covered product equivalent to an FDA approval when statutory criteria are satisfied. Practically, it replaces an initial FDA marketing review with a reliance decision that focuses on whether the foreign authorization exists, whether U.S. approval is absent, and whether either jurisdiction has withdrawn approval for safety reasons. It also makes the reciprocal product subject to the full panoply of FD&C Act provisions once approved, so labeling, manufacturing controls, and enforcement authorities apply similarly to domestically approved products.
What sponsors must show to be eligible
The bill requires sponsors to prove four things: a lawful foreign marketing authorization from a trusted regulator; that the product is not already approved in the U.S.; that no relevant approval has been rescinded for safety; and that the product targets an immediately life‑threatening condition. This limits the program to high‑need indications while tying eligibility to foreign regulatory continuity and the FDA’s confidence in the foreign authorization.
Submission requirements, 30‑day decision clock, and post‑market setup
Sponsors must submit dossiers (with English translations) and any additional information the Secretary requires. The FDA must finalize labeling and identify necessary post‑market studies within the 30‑day statutory window. Treating requests as applications under chapter VII means sponsors pay user fees; however, the statute does not spell out specific fee amounts, leaving implementation to existing fee schedules. By making labeling and post‑market study decisions part of the 30‑day process, the bill effectively converts much of premarket review work into rapid decisioning and subsequent surveillance.
Grounds and practical options for removing products
The Secretary may suspend or withdraw reciprocal approval if new clinical or real‑world data show unreasonable risks or if the originating foreign regulator rescinds approval. If adverse events surface within the first 30 days after approval, the statute authorizes immediate public notice and potential cessation of distribution; alternatively, FDA may implement phased withdrawals with patient‑transition measures. This gives the agency operational flexibility but places a premium on rapid signal detection and contingency planning.
Fee treatment and congressional reporting requirement
The statute treats reciprocal requests as fee‑paying applications under chapter VII, integrating them into PDUFA‑style funding structures and signaling that the program must be resourced through user fees. The five‑year report requirement obliges the agency to evaluate program effectiveness, safety impacts, and whether the pathway should continue, change, or end — creating an explicit legislative review point tied to measurable outputs (numbers granted/denied, safety signals, access metrics).
Reciprocal allowance for clinical investigations
This new section lets manufacturers request permission to run in the U.S. the same clinical trial a trusted foreign regulator has already authorized. The agency must treat the submission as meeting IND criteria and decide within 30 days; it can request protocol changes but must still conclude within that time. The provision applies to ‘qualified products’ (covered products for immediately life‑threatening diseases) and mirrors the marketing‑approval path’s emphasis on speed and reliance on foreign assessment.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with immediately life‑threatening or rare diseases — gain potential earlier access to therapies authorized abroad and earlier opportunities to enroll in trials that would otherwise remain overseas.
- Sponsors and biopharmaceutical developers — face faster U.S. entry for certain products, reduced duplicative premarket review, and clearer predictability around timing, potentially lowering commercial risk for high‑need programs.
- U.S. clinical trial sites and investigators — can host studies already authorized abroad, increasing recruitment opportunities and preserving U.S. trial participation for innovative programs.
- Investors and developers focused on small‑population indications — speed to market can improve investment returns and make U.S. commercialization more viable for niche products.
Who Bears the Cost
- FDA — must process rapid 30‑day reliance requests, finalize labeling and post‑market plans quickly, and expand surveillance and signal‑detection capacity to manage increased post‑market risk exposure.
- Manufacturers — must assemble and translate foreign dossiers, pay chapter VII user fees, and be ready to perform expedited post‑market studies or manage sudden withdrawals and transition plans.
- Payers and health systems — may need to decide on coverage and budget for high‑cost treatments authorized under this expedited reliance track with compressed U.S. review of premarket evidence.
- Clinical trial oversight bodies (IRBs, hospitals) — will absorb administrative and monitoring burdens for trials entering the U.S. on reliance, including potential protocol modification requests on short notice.
Key Issues
The Core Tension
The central dilemma is speed versus sovereign review: the bill accelerates patient access by relying on trusted foreign decisions, but doing so reduces the time and depth of U.S. premarket assessment and places greater weight on post‑market surveillance and on subjective judgments about which foreign regulators to trust. Policymakers must choose between faster access today and potentially greater uncertainty about safety and long‑term evidence tomorrow.
The bill shifts the locus of regulatory risk from premarket review to post‑market surveillance. By compressing the agency decision window to 30 days and requiring that labeling and post‑market commitments be settled in that period, the statute assumes FDA retains sufficient surveillance tools to detect and act on safety signals quickly.
If the agency lacks personnel, analytic capacity, or data‑sharing arrangements with foreign counterparts, that assumption may not hold — increasing the chance of late safety surprises.
The statute delegates substantial discretion to the HHS Secretary to designate additional “trusted” regulators beyond EMA, MHRA, and Health Canada. That discretion is operationally sensible but raises questions about objective criteria, potential geopolitical influence, and reciprocal expectations from partner regulators.
Separately, treating requests as chapter VII fee applications provides a funding mechanism but does not guarantee that fee levels or hiring authorities will match the different skill set needed for rapid reliance decisions and intensive post‑market surveillance.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.